Parkinson’s Disease Study

Parkinson’s Disease is a neurodegenerative disease that attacks the part of the brain that handles motor functions (ie: movement and posture). Many of the early symptoms of Parkinson’s Disease are shaking, muscle tremors, having difficulty walking, and an overall slowing of movement. As Parkinson’s progresses, emotional and cognitive changes can occur like depression, anxiety, and dementia. Most people are diagnosed with Parkinson’s Disease in their 60’s, with some rare early onset cases occurring in people prior to age 50. Parkinson’s Disease does not have a cure at this time, but treatments are being developed to slow its progression and eliminate some of the symptoms. Here at New England Institute for Clinical Research, we are working to bring these treatments to patients suffering with this disease.


Inhibikase IkT-148009-201
This study is designed to evaluate the safety and efficacy of the medication IkT-148009 in
treating Parkinson’s Disease (PD) for people who are 30-80 years of age and have not
received previous PD treatment. AkT-148009 works to inhibit the formation and effects of a
toxic protein in the brain that is believed to contribute to the degeneration and symptoms
seen in PD. Unlike most current standard treatments for PD, which only treat symptoms,
this medication has the potential to slow the progression of the underlying disease. The
study consists of a 12-week treatment period, during which time eligible patients will take
either one of three doses of the study medication or a placebo by mouth once daily with
food. The study will last about 18 weeks, including a screening period and a safety followup.

Learn more: https://clinicaltrials.gov/study/NCT05424276

Precision 1009
The objective of this study is to collect laboratory samples from individuals diagnosed with
Parkinson’s disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy
(PSP), and Corticobasal Syndrome. The samples collected include DNA, RNA, serum,
plasma, cerebrospinal fluid (CSF), urine, and saliva. Visit 1 consists of informed consent,
study-specific assessments, a blood draw, and a lumbar puncture (spinal tap). All following
visits will occur at 6-month intervals at the discretion of the Principal Investigator (PI) of the
study. The samples are stored for future research to aid in understanding the disease and
future treatment development. 


All studies and study related procedures are provided at no cost to you. There may be compensation to you for your time and travel. Participation is completely voluntary, meaning that you can withdraw at any time. If you are interested, please fill out the form below or give us a call at 203-914-1903.